|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
T cell receptor platform
|
|
gptkbp:ceo
|
gptkb:Bahija_Jallal
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaboration
|
gptkb:University_of_California
gptkb:University_of_Oxford
|
|
gptkbp:focus
|
T cell receptor technology
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founder
|
gptkb:Bahija_Jallal
|
|
gptkbp:funding
|
gptkb:Series_B
Series C
IPO
|
|
gptkbp:headquarters
|
gptkb:Oxford,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Immunocore
|
|
gptkbp:instruction_set
|
T cell engagers
bispecific antibodies
|
|
gptkbp:investment
|
$100 million
|
|
gptkbp:number_of_employees
|
100-200
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly
gptkb:Merck
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Janssen
gptkb:Pfizer
gptkb:Roche
gptkb:Bayer
gptkb:Amgen
gptkb:Sandoz
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Novartis
gptkb:Takeda
gptkb:Astellas
|
|
gptkbp:product
|
gptkb:IMCgp100
IMC-C103 C
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research_areas
|
gptkb:Oncology
autoimmune diseases
|
|
gptkbp:research_focus
|
gptkb:immunotherapy
solid tumors
cellular therapy
hematological malignancies
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:technology
|
T cell activation
TCRs
tumor targeting
|
|
gptkbp:trade
|
IMCR
|
|
gptkbp:website
|
www.immunocore.com
|
|
gptkbp:bfsParent
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:bfsLayer
|
5
|